BR112016018099B8 - Compostos funcionalizados de benzopiranos e uso dos mesmos - Google Patents

Compostos funcionalizados de benzopiranos e uso dos mesmos

Info

Publication number
BR112016018099B8
BR112016018099B8 BR112016018099A BR112016018099A BR112016018099B8 BR 112016018099 B8 BR112016018099 B8 BR 112016018099B8 BR 112016018099 A BR112016018099 A BR 112016018099A BR 112016018099 A BR112016018099 A BR 112016018099A BR 112016018099 B8 BR112016018099 B8 BR 112016018099B8
Authority
BR
Brazil
Prior art keywords
functionalized
benzopyran compounds
present
compounds
benzopyran
Prior art date
Application number
BR112016018099A
Other languages
English (en)
Other versions
BR112016018099A2 (pt
BR112016018099B1 (pt
Inventor
Heaton Andrew
Brown David
Kelly Graham
Original Assignee
Novogen ltd
Kazia Therapeutics Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Novogen ltd, Kazia Therapeutics Ltd filed Critical Novogen ltd
Publication of BR112016018099A2 publication Critical patent/BR112016018099A2/pt
Publication of BR112016018099B1 publication Critical patent/BR112016018099B1/pt
Publication of BR112016018099B8 publication Critical patent/BR112016018099B8/pt

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D311/00—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only hetero atom, condensed with other rings
    • C07D311/02—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only hetero atom, condensed with other rings ortho- or peri-condensed with carbocyclic rings or ring systems
    • C07D311/04—Benzo[b]pyrans, not hydrogenated in the carbocyclic ring
    • C07D311/06—Benzo[b]pyrans, not hydrogenated in the carbocyclic ring with oxygen or sulfur atoms directly attached in position 2
    • C07D311/08—Benzo[b]pyrans, not hydrogenated in the carbocyclic ring with oxygen or sulfur atoms directly attached in position 2 not hydrogenated in the hetero ring
    • C07D311/16—Benzo[b]pyrans, not hydrogenated in the carbocyclic ring with oxygen or sulfur atoms directly attached in position 2 not hydrogenated in the hetero ring substituted in position 7
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D311/00—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only hetero atom, condensed with other rings
    • C07D311/02—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only hetero atom, condensed with other rings ortho- or peri-condensed with carbocyclic rings or ring systems
    • C07D311/04—Benzo[b]pyrans, not hydrogenated in the carbocyclic ring
    • C07D311/58—Benzo[b]pyrans, not hydrogenated in the carbocyclic ring other than with oxygen or sulphur atoms in position 2 or 4
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/35—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom
    • A61K31/352—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom condensed with carbocyclic rings, e.g. methantheline 
    • A61K31/353—3,4-Dihydrobenzopyrans, e.g. chroman, catechin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D407/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having oxygen atoms as the only ring hetero atoms, not provided for by group C07D405/00
    • C07D407/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having oxygen atoms as the only ring hetero atoms, not provided for by group C07D405/00 containing two hetero rings
    • C07D407/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having oxygen atoms as the only ring hetero atoms, not provided for by group C07D405/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D407/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having oxygen atoms as the only ring hetero atoms, not provided for by group C07D405/00
    • C07D407/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having oxygen atoms as the only ring hetero atoms, not provided for by group C07D405/00 containing two hetero rings
    • C07D407/10—Heterocyclic compounds containing two or more hetero rings, at least one ring having oxygen atoms as the only ring hetero atoms, not provided for by group C07D405/00 containing two hetero rings linked by a carbon chain containing aromatic rings

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Epidemiology (AREA)
  • Oncology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Pyrane Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Low-Molecular Organic Synthesis Reactions Using Catalysts (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

COMPOSTOS FUNCIONALIZADOS DE BENZOPIRANOS E USO DOS MESMOS. A presente invenção refere-se amplamente a agentes anticâncer. Em particular, a presente invenção refere-se à compostos selecionados de benzopiranos, preparação dos mesmos, e utilização dos mesmos em métodos para o tratamento de câncer e na redução da incidência ou risco de recorrência de câncer.
BR112016018099A 2014-02-07 2015-02-05 Compostos funcionalizados de benzopiranos e uso dos mesmos BR112016018099B8 (pt)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US201461937368P 2014-02-07 2014-02-07
US61/937,368 2014-02-07
US201461987323P 2014-05-01 2014-05-01
US61/987,323 2014-05-01
PCT/AU2015/050040 WO2015117202A1 (en) 2014-02-07 2015-02-05 Functionalised benzopyran compounds and use thereof

Publications (3)

Publication Number Publication Date
BR112016018099A2 BR112016018099A2 (pt) 2017-08-08
BR112016018099B1 BR112016018099B1 (pt) 2022-10-11
BR112016018099B8 true BR112016018099B8 (pt) 2023-01-17

Family

ID=53777071

Family Applications (1)

Application Number Title Priority Date Filing Date
BR112016018099A BR112016018099B8 (pt) 2014-02-07 2015-02-05 Compostos funcionalizados de benzopiranos e uso dos mesmos

Country Status (25)

Country Link
US (2) US9701655B2 (pt)
EP (1) EP2953938B1 (pt)
JP (1) JP6570042B2 (pt)
KR (1) KR102395543B1 (pt)
CN (2) CN105980372B (pt)
AU (1) AU2015213484B2 (pt)
BR (1) BR112016018099B8 (pt)
CA (1) CA2936012C (pt)
CL (1) CL2016001937A1 (pt)
DK (1) DK2953938T3 (pt)
ES (1) ES2643407T3 (pt)
HK (1) HK1218914A1 (pt)
IL (1) IL241515B (pt)
LT (1) LT2953938T (pt)
MX (1) MX368063B (pt)
MY (1) MY195739A (pt)
NZ (1) NZ711603A (pt)
PH (1) PH12016501422A1 (pt)
PL (1) PL2953938T3 (pt)
PT (1) PT2953938T (pt)
RU (1) RU2676766C2 (pt)
SA (1) SA516371583B1 (pt)
SG (2) SG11201604490SA (pt)
SI (1) SI2953938T1 (pt)
WO (1) WO2015117202A1 (pt)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
NZ711603A (en) * 2014-02-07 2017-05-26 Novogen ltd Functionalised benzopyran compounds and use thereof
PL3253208T3 (pl) 2015-02-02 2021-11-08 Mei Pharma, Inc. Terapie kombinowane do zastosowania w leczeniu nowotworu piersi
US10265294B2 (en) * 2016-03-31 2019-04-23 Yale University Compositions and methods for treating epithelial cancer
WO2017173498A1 (en) 2016-04-06 2017-10-12 Noxopharm Limited Isoflavonoid composition with improved pharmacokinetics
CA3058492A1 (en) * 2016-04-06 2017-10-12 Noxopharm Limited Radiotherapy improvements
CN109793737B (zh) * 2017-03-01 2021-06-29 浙江大学 苯磺酰胺结构类型雄激素受体拮抗剂及其应用
JP2023519990A (ja) 2020-03-30 2023-05-15 ノクソファーム リミティド 感染に関連する炎症の治療のための方法
EP4164632A4 (en) * 2020-06-11 2024-06-05 MEI Pharma, Inc. COMBINATION THERAPIES
WO2023235929A1 (en) * 2022-06-08 2023-12-14 Noxopharm Limited Functionalised benzopyran compounds and uses thereof

Family Cites Families (62)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3340276A (en) 1964-04-01 1967-09-05 Ciba Geigy Corp 3, 4-diphenyl-chromans
US3822287A (en) 1969-04-17 1974-07-02 Rexall Drug Chemical Process for preparation of substituted 3,4-(diphenyl)chromans
US4447622A (en) 1981-09-22 1984-05-08 Council Of Scientific And Industrial Research Rafi Marg Preparation of l- and d-isomers of dl-3,4-trans-2,2-disubstituted-3,4-diarylchromans and derivatives thereof
BE891562A (fr) 1981-12-21 1982-04-16 Council Scient Ind Res Isomeres 1 et d de d1-3, 4-trans-3, 4-diarylchromanes 2, 2-disubstitues et leurs derives, leur preparation et leur utilisation
US5451603A (en) 1993-03-11 1995-09-19 Zymogenetics, Inc. 3,4-diarylchromans for treatment of dermatitis
US5280040A (en) 1993-03-11 1994-01-18 Zymogenetics, Inc. Methods for reducing bone loss using centchroman derivatives
JPH10511960A (ja) 1995-01-13 1998-11-17 ノボ ノルディスク アクティーゼルスカブ 特発性の又は生理学的な女性化乳房の治療又は予防のための医薬製剤の製造のための３，４−ジフェニル・クロマンの使用
HUP9800521A3 (en) 1995-01-13 1999-12-28 Novo Nordisk As Use of 3,4-diphenyl chromans for the manufacture of a pharmaceutical composition for the treatment or propylaxis of hyperlipoproteinaemia, hypertriglyceridaemia, hyperlipidaemia or hypercholesterolaemia or arteriosclerosis
HUP9702244A3 (en) 1995-01-13 1999-12-28 Novo Nordisk As Use of 3,4-diphenyl chromans for manufacture of a pharmaceutical composition for treatment or prophylaxis of gynaecological disorders
KR19980701548A (ko) 1995-01-20 1998-05-15 슈타르 피아 혈관확장치료 또는 예방용 약학적 조성물의 제조를 위한 3,4-디페닐크로만의 이용(use of 3,4-diphenyl chromans for the manufacture of a pharmaceutical composition for vasodilatory treatment or prophylaxis)
CZ212097A3 (en) 1995-01-20 1997-11-12 Novo Nordisk As Use of 3,4-diphenylchromans for preparing a medicament intended for treating or prophylaxis of cerebral degenerative diseases
TW448046B (en) 1995-01-20 2001-08-01 Novo Nordisk As Use of 3,4-diphenyl chromans for the manufacture of a pharmaceutical composition for the treatment or prophylaxis of obesity
US5726202A (en) 1996-01-11 1998-03-10 Novo Nordisk A/S Benign prostatic hypertrophy
CN1207038A (zh) 1996-01-11 1999-02-03 诺沃挪第克公司 3,4－二苯基苯并二氢吡喃在生产预防或治疗绝经症状的药物组合物中的应用
AU1367297A (en) 1996-01-11 1997-08-01 Novo Nordisk A/S Use of 3,4-diphenyl chromans for the manufacture of a pharmaceutical comp osition for the treatment or prophylaxis of menopausal symptoms
US5747059A (en) 1996-01-11 1998-05-05 Novo Nordisk A/S Atrophy of skin/mucous membrane
US5883118A (en) 1996-01-11 1999-03-16 Nova Nordisk A/S Prostatic carcinoma
US5756539A (en) 1996-07-11 1998-05-26 Novo Nordis A/S 3, 4-diphenyl chromans for inhibiting one or more psychiatric disorders
US5780502A (en) 1996-07-12 1998-07-14 Novo Nordisk A/S Use of 3,4-diphenyl chromans for the manufacture of a pharmaceutical composition for inhibiting one or more symptoms of premenstrual syndrome
US6043269A (en) 1996-10-28 2000-03-28 Novo Nordisk A/S cis-3,4-chroman derivatives useful in the prevention or treatment of estrogen related diseases or syndromes
CA2270111A1 (en) 1996-10-28 1998-05-07 Lise Brown Christiansen Novel (-)-enantiomers of cis-3,4-chroman derivatives useful in the prevention or treatment of estrogen related diseases or syndromes
US5925771A (en) 1996-10-28 1999-07-20 Novo Nordisk A/S Process for the preparation of (-)-3,4-trans-diarylchromans
US5919817A (en) 1996-10-28 1999-07-06 Novo Nordisk A/S Cis-3, 4-chroman derivatives useful in the prevention or treatment of estrogen related diseases or syndromes
JP2001502705A (ja) * 1996-10-28 2001-02-27 ノボ ノルディスク アクティーゼルスカブ エストロゲン関係疾患または症候群の予防または治療において有用な新規なシス―３，４―クロマン誘導体
WO1998033500A1 (en) 1997-01-29 1998-08-06 Novo Nordisk A/S Use of 3,4-diphenyl chromans for the manufacture of a pharmaceutical composition for inhibiting senescence-associated motor impairment
WO1998033499A1 (en) 1997-01-29 1998-08-06 Novo Nordisk A/S Use of 3,4-diphenyl chromans for the manufacture of a pharmaceutical composition for increasing libido in post-menopausal women
US6184005B1 (en) 1998-04-28 2001-02-06 Novo Nordisk A/S Enzymatic resolvation for obtaining a (−)-3,4-trans-diarylchroman
CA2345079C (en) * 1998-09-23 2011-06-21 Research Development Foundation Tocopherols, tocotrienols, other chroman and side chain derivatives and uses thereof
AU6315300A (en) 1999-07-26 2001-02-13 Shionogi & Co., Ltd. Benzene derivatives and immunopotentiating compositions or drug-sensitivity restoring agents containing the same
US7226945B2 (en) 2000-10-13 2007-06-05 Astrazeneca Ab Estrogen receptor-β ligands
US20050119301A1 (en) 2001-03-16 2005-06-02 Alan Husband Treatment of restenosis
WO2002074307A1 (en) 2001-03-16 2002-09-26 Novogen Research Pty Ltd Treatment of restenosis
WO2003063859A1 (en) 2002-01-14 2003-08-07 Nordic Bioscience A/S Suppression of cartilage degradation via the estrogen receptor
US20040167165A1 (en) 2003-01-16 2004-08-26 Geetha Shankar Methods of treating conditions associated with an Edg-7 receptor
EP1634958B1 (en) 2003-06-04 2009-02-18 Mitsubishi Gas Chemical Company, Inc. Method for producing optically active chroman-carboxylate
CA2542351A1 (en) * 2003-11-19 2005-06-02 Novogen Research Pty Ltd. Combinational radiotherapy and chemotherapy compositions and methods
JP4913056B2 (ja) * 2004-09-21 2012-04-11 マーシャル エドワーズ，インコーポレーテッド 置換クロマン誘導体、医薬品、および治療における使用
ATE532777T1 (de) 2004-09-21 2011-11-15 Marshall Edwards Inc Substituierte chromanderivate, medikamente und anwendungen in der therapie
US8080675B2 (en) 2004-09-21 2011-12-20 Marshall Edwards, Inc. Chroman derivatives, medicaments and use in therapy
JP4976649B2 (ja) * 2004-09-21 2012-07-18 マーシャル エドワーズ，インク． 化合物
WO2006032086A1 (en) 2004-09-21 2006-03-30 Novogen Research Pty Ltd Chroman derivatives, medicaments and use in therapy
US7528267B2 (en) 2005-08-01 2009-05-05 Girindus America, Inc. Method for enantioselective hydrogenation of chromenes
EP1991220A1 (en) 2006-02-21 2008-11-19 Trigen Limited Heterocyclic compounds and their use in the treatment of cardiovascular disease
US20100152284A1 (en) 2006-10-30 2010-06-17 Novogen Research Pty Ltd Prevention and reversal of chemotherapy-induced peripheral neuropathy
CN101210012B (zh) 2006-12-31 2011-09-14 南华大学 新的含烟酸异黄酮酯衍生物及其制造方法和用途
CA2738328A1 (en) 2008-08-29 2010-03-04 Novogen Research Pty Ltd Immunomodulating activities
WO2010045674A1 (en) 2008-10-22 2010-04-29 Novogen Research Pty Ltd Methods for inducing programmed cell death
AU2008230055A1 (en) 2008-10-22 2010-05-06 Novogen Research Pty Ltd Methods for Inducing Programmed Cell Death
WO2011115819A2 (en) 2010-03-15 2011-09-22 Genus Oncology, Llc Small molecule inhibitors of muc1 and methods of identifying the same
WO2011156889A1 (en) 2010-06-14 2011-12-22 Trt Pharma Inc. Novel modulators of nrf2 and uses thereof
EP2635121B1 (en) 2010-11-01 2020-01-08 MEI Pharma, Inc. Isoflavonoid compounds and methods for the treatment of cancer
CN102153535A (zh) 2011-03-04 2011-08-17 中国海洋大学 一种抗肿瘤多药耐药抑制剂苯并吡喃-3-醇酯化衍生物及其制备方法和应用
US20120251630A1 (en) * 2011-03-29 2012-10-04 Marshall Edwards, Inc. Remission therapy of cancer with isoflavonoids
WO2013026942A1 (en) * 2011-08-25 2013-02-28 The Provost, Fellows, Foundation Scholars, And The Other Members Of Board, Of The College Of The Holy And Undivided Trinity Of Queen Elizabeth, Near Dublin Tubulin binding agents
US9957247B2 (en) 2012-06-07 2018-05-01 Georgia State University Research Foundation, Inc. SecA inhibitors and methods of making and using thereof
CN103408528B (zh) 2013-08-13 2015-04-29 浙江大学 一种色满化合物及其制备方法和应用
CN103450142B (zh) 2013-09-04 2015-03-25 浙江大学 一种色满化合物及其提取方法和应用
CN103585145A (zh) 2013-11-28 2014-02-19 常州科立信医疗器械有限公司 Artoxanthochromane在治疗前列腺癌药物中的应用
CN103638008B (zh) 2013-12-02 2015-09-16 刘艳娇 Artoxanthochromane在治疗皮肤癌药物中的应用
CN103690525A (zh) 2013-12-02 2014-04-02 常州科立信医疗器械有限公司 Artoxanthochromane在治疗舌癌药物中的应用
CN103705503A (zh) 2013-12-04 2014-04-09 常州科立信医疗器械有限公司 Artoxanthochromane在治疗乳腺癌药物中的应用
NZ711603A (en) * 2014-02-07 2017-05-26 Novogen ltd Functionalised benzopyran compounds and use thereof

Also Published As

Publication number Publication date
AU2015213484A1 (en) 2015-09-17
SG11201506988TA (en) 2015-10-29
CA2936012A1 (en) 2015-08-13
PL2953938T3 (pl) 2017-12-29
PH12016501422B1 (en) 2016-08-31
EP2953938A4 (en) 2016-08-10
MX2016010137A (es) 2017-02-15
JP2017507175A (ja) 2017-03-16
CN105980372B (zh) 2018-05-08
BR112016018099A2 (pt) 2017-08-08
RU2016133731A3 (pt) 2018-08-08
IL241515B (en) 2019-06-30
RU2016133731A (ru) 2018-03-12
SI2953938T1 (en) 2018-01-31
US20160340329A1 (en) 2016-11-24
JP6570042B2 (ja) 2019-09-04
SG11201604490SA (en) 2016-07-28
CL2016001937A1 (es) 2017-01-20
BR112016018099B1 (pt) 2022-10-11
IL241515A0 (en) 2015-11-30
PT2953938T (pt) 2017-10-09
KR102395543B1 (ko) 2022-05-09
CN105980372A (zh) 2016-09-28
RU2676766C2 (ru) 2019-01-11
MY195739A (en) 2023-02-08
CN108484559A (zh) 2018-09-04
HK1218914A1 (zh) 2017-03-17
SA516371583B1 (ar) 2019-04-18
LT2953938T (lt) 2017-10-10
ES2643407T3 (es) 2017-11-22
AU2015213484B2 (en) 2015-11-05
PH12016501422A1 (en) 2016-08-31
US10370349B2 (en) 2019-08-06
MX368063B (es) 2019-09-18
US9701655B2 (en) 2017-07-11
EP2953938B1 (en) 2017-08-02
WO2015117202A1 (en) 2015-08-13
NZ711603A (en) 2017-05-26
US20180141925A1 (en) 2018-05-24
EP2953938A1 (en) 2015-12-16
CA2936012C (en) 2023-03-07
KR20160110427A (ko) 2016-09-21
DK2953938T3 (en) 2017-10-02

Similar Documents

Publication Publication Date Title
BR112016018099B8 (pt) Compostos funcionalizados de benzopiranos e uso dos mesmos
BR112017010324A2 (pt) método para tratar ou retardar a progressão de um câncer em um indivíduo, moléculas, métodos para aumentar a função imune em um indivíduo e para selecionar um paciente para tratamento, kits, composição farmacêutica e usos de uma combinação de uma molécula
CL2016002514A1 (es) Uso de dianhidrogalactilol y análogos o derivados del mismo para tratar células no pequeñas de carcinoma de pulmón y cáncer de ovarios
BR112018012138A2 (pt) moléculas de anticorpo para pd-1 e usos das mesmas
BR112018010089A2 (pt) composições compreendendo cepas bacterianas
BR112017000664A2 (pt) anticorpo anti-pd-1 e seu uso
BR112016017256A2 (pt) combinação de um antagonista de pd-1 e um inibidor de vegfr para o tratamento de câncer
EA201992251A1 (ru) Противораковые вакцины и способы лечения с их применением
EP3348276A4 (en) CANCER TREATMENT COMPOSITION COMPRISING ANTI-CD26 ANTIBODY AND ANOTHER CANCER AGENT
BR112017011771A2 (pt) métodos e composições para o tratamento de câncer
BR112017008799A2 (pt) composições de apilimod e métodos de uso das mesmas no tratamento de câncer renal
BR112016017112A2 (pt) Composições de apilimod e métodos de uso das mesmas
BR112018008103A2 (pt) análogos de celastrol
BR112016027043A2 (pt) Combinação, composição farmacêutica compreendendo glucocorticoide e edo-s101, kit e uso no tratamento de câncer
BR112018000776A2 (pt) métodos para tratamento de câncer usando apilimod
BR112018075135A2 (pt) combinações farmacêuticas para tratar câncer
BR112016026545A2 (pt) eribulina ou um sal farmaceuticamente aceitável do mesmo, seus usos e kit para utilização no tratamento de câncer da mama
BR112017025255A2 (pt) métodos, produto, produto de programa de computador, sistema, e composições farmacêuticas estimulante e inibidora para uso no tratamento ou prevenção do câncer de próstata
BR112016029842A2 (pt) conjugados de anticorpo anti-cd22-fármaco e métodos de uso dos mesmos
CL2016003074A1 (es) Compuestos derivados de 2-oxi-2-fenil-n-5-pirrolidin-3-ilamino-1,3,4-tiadiazol-2-ilacetamida, inhibidores gls1 composición farmacéutica y su uso para tratar el cáncer.
BR112017009265A2 (pt) apilimode para uso no tratamento do câncer colorretal
BR112017022022A8 (pt) Arenavírus para uso no tratamento e/ou prevenção de tumores e método para a produção de arenavírus com propriedades de regressão de tumor (aprimoradas)
BR112018013272A2 (pt) composições e métodos para detectar e tratar câncer esofágico
BR112017011685A2 (pt) composições compreendendo 15-hepe e métodos de tratamento ou prevenção da fibrose usando as mesmas
BR112019020414A2 (pt) composições e métodos para detectar e tratar câncer de próstata usando moléculas de ligação à progastrina

Legal Events

Date Code Title Description
B07D Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette]
B07E Notification of approval relating to section 229 industrial property law [chapter 7.5 patent gazette]
B06U Preliminary requirement: requests with searches performed by other patent offices: procedure suspended [chapter 6.21 patent gazette]
B07A Application suspended after technical examination (opinion) [chapter 7.1 patent gazette]
B15G Petition not considered as such [chapter 15.7 patent gazette]
B09A Decision: intention to grant [chapter 9.1 patent gazette]
B16A Patent or certificate of addition of invention granted [chapter 16.1 patent gazette]

Free format text: PRAZO DE VALIDADE: 20 (VINTE) ANOS CONTADOS A PARTIR DE 05/02/2015, OBSERVADAS AS CONDICOES LEGAIS

B16C Correction of notification of the grant [chapter 16.3 patent gazette]

Free format text: REFERENTE A RPI 2701 DE 11/10/2022, QUANTO AO ITEM (73) ENDERECO DO TITULAR.

B25D Requested change of name of applicant approved

Owner name: KAZIA THERAPEUTICS LIMITED (AU)

B25G Requested change of headquarter approved

Owner name: KAZIA THERAPEUTICS LIMITED (AU)

B25G Requested change of headquarter approved

Owner name: KAZIA THERAPEUTICS LIMITED (AU)